Phycus Biotechnologies
Toronto
About Phycus Biotechnologies
Phycus Biotechnologies provides a bio-conversion platform intended to convert CO2 and diverting GHG emissions from large scale emitters. The company's platform combines microbial technology and metabolic engineering techniques that capture and convert carbon dioxide in to high valued chemical building blocks which are found in a variety of industrial products and applications, enabling businesses to find an alternative route for recycling CO2 into fuels and chemicals, economically, while reducing the overall GHG footprint.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $73.5K
- Funding stage: Seed
- Last round: Seed (Jul 2020)
- Website: phycusbio.com
Industries & Categories
Biomass Energy, Biotechnology, Environmental Engineering, Life Science
Social Profiles
Canonical: https://fsome.com/organization/phycus-biotechnologies-207064 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.